The Journal of Pediatrics
Volume 158, Issue 1 , Pages 106-111 , January 2011

Glycemic Control in Youth with Type 2 Diabetes Declines as Early as Two Years after Diagnosis

Presented in part in the at the 2008 Eastern Society for Pediatric Research Annual Meeting, Philadelphia, Pennsylvania, and the 2008 Society for Pediatric Research Annual Meeting, Honolulu, Hawaii.

Received 24 November 2009 ,Revised 17 June 2010 ,Accepted 9 July 2010.

References 

  1. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care. 2000;23:381
  2. Fagot-Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr. 2000;136:664–672
  3. Lipman TH, Levitt Katz LE, Aguilar A, Murphy KM, Ratcliffe SJ, Suarez E. The epidemiology of type 1 and type 2 diabetes in youth in Philadelphia: 2000-2004. Diabetes. 2009;58(Suppl 1):A77
  4. Kahn S. Clinical review 135—the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86:4047–4058
  5. Gungor N, Arslanian S. Progressive beta cell failure in type 2 diabetes mellitus of youth. J Pediatr. 2004;144:656–659
  6. Polonsky KS. The beta cell in diabetes: from molecular genetics to clinical research. Diabetes. 1995;44:705–717
  7. Maddux BA, Chan A, De Filippis EA, Mandarino LJ, Goldfine ID. IGF-binding protein-1 levels are related to insulin-mediated glucose disposal and are a potential serum marker of insulin resistance. Diabetes Care. 2006;29:1535–1537
  8. Levitt Katz LE, Jawad AF, Ganesh J, Abraham M, Murphy K, Lipman TH. Fasting c-peptide and insulin-like growth factor-binding protein-1 levels help to distinguish childhood type 1 and type 2 diabetes at diagnosis. Pediatr Diabetes. 2007;8:53–59
  9. SPSS for Windows. Release 15. Chicago: SPSS Inc.; 2006;
  10. Ferrannini E, Nannipieri M, Williams K, Gonzales C, Haffner SM, Stern MP. Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes. 2004;53:160–165
  11. Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, Nissen M, et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes. 2005;54:166–174
  12. Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia study. Diabetes. 2000;49:975–980
  13. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: sulphonylurea failure in non-insulindependent diabetic patients over six years UK prospective diabetes study. Diabet Med. 1998;15:297–303
  14. Elder DA, Prigeon RL, Wadwa RP, Dolan LM, D'Alessio DA. Beta-cell function, insulin sensitivity, and glucose tolerance in obese diabetic and nondiabetic adolescents and young adults. J Clin Endocrinol Metab. 2006;91:185–191
  15. Kobayashi K, Amemiya S, Higashida K, Ishihara T, Sawanobori E, Kobayashi K, et al. Pathogenic factors of glucose intolerance in obese Japanese adolescents with type 2 diabetes. Metabolism. 2000;49:186–191
  16. Druet C, Tubiana-Rufi N, Chevenne D, Rigal O, Polak M, Levy-Marchal C. Characterization of insulin secretion and resistance in type 2 diabetes of adolescents. J Clin Endocrinol Metab. 2006;91:401–404
  17. Taha D, Umpaichitra V, Banerji MA, Castells S. Type 2 diabetes mellitus in African-American adolescents: Impaired beta-cell function in the face of severe insulin resistance. J Pediatr Endocrinol Metab. 2006;19:135–142
  18. UK Prospective Diabetes Grp. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes. Lancet. 1998;352:854–865
  19. Ostgren CJ, Lindblad U, Ranstam J, Melander A, Rastam L. Glycaemic control, disease duration and beta-cell function in patients with type 2 diabetes in a Swedish community. Skaraborg hypertension and diabetes project. Diabet Med. 2002;19:125–129
  20. Gungor N, Bacha F, Saad R, Janosky J, Arslanian S. Youth type 2 diabetes: insulin resistance, beta-cell failure, or both?. Diabetes Care. 2005;28:638–644
  21. Cruickshank JK, Heald AH, Anderson S, Cade JE, Sampayo J, Riste LK, et al. Epidemiology of the insulin-like growth factor system in three ethnic groups. Am J Epidemiol. 2001;154:504–513
  22. Weiss R, Caprio S, Trombetta M, Taksali SE, Tamborlane WV, et al. Beta- cell function across the spectrum of glucose tolerance in obese youth. Diabetes. 2005;54:1735–1743
  23. Chen QY, Rowley MJ, Byrne GC, Jones TW, Tuomi T, Knowles WJ, et al. Antibodies to glutamic acid decarboxylase in Australian children with insulin-dependent diabetes mellitus and their first degree relatives. Pediatr Res. 1993;34:785–790
  24. Vandewalle CL, Falorni A, Svanholm S, Lernmark A, Pipeleers DG, Gorus FK, et al. High diagnostic sensitivity of glutamic acid decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years. J Clin Endocrinol Metab. 1995;80:846–851
  25. Bonifacio E, Genovese S, Braghi S, Bassigaluppie E, Lampasona V, Bingley PJ, et al. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia. 1995;38:816–822
  26. Ng WY, Ys Lee, Todd AL, Lui KF, Loke KY, Thai AC. Tyrosine phosphatase-like protein (IA-2) and glutamic acid decarboxylase (GAD65) autoantibodies: a study of Chinese patients with diabetes mellitus. Autoimmunity. 2002;35:119–124
  27. Pietropaolo M, Peakman M, Pietropaolo SL, Zanone MM, Foley TP, Becker DJ, et al. Combined analysis of GAD65 and ICA512 (IA-2) autoantibodies in organ and non-organ specific autoimmune diseases confers high specificity for insulin-dependent diabetes mellitus. J Autoimmun. 1998;11:1–10
  28. Gorus FK, Goubert P, Semakula C, Vandewalle CL, DeSchepper J, Scheen A, et al. IA-2-autoantibodies complement GAD(65)-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. Diabetologia. 1997;40:95–99
  29. SEARCH Diabet Youth Study Grp. Diabetes in African American youth: prevalence, incidence, and clinical characteristics: the SEARCH for diabetes in youth study. Diabetes Care. 2009;32(Suppl. 2):S112–S122
  30. Pinhas-Hamiel O, Dolan LM, Zeitler PS. Diabetic ketoacidosis among obese African-American adolescents with NIDDM. Diabetes Care. 1997;20:484–486
  31. Winter WE. Atypical diabetes in blacks. Clin Diabetes. 1991;9:51–56
  32. Banerji MA, Chaiken RL, Huey H, Tuomi T, Norin AJ, Mackay IR, et al. GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of HLA DR3 and DR4: Flatbush Diabetes. Diabetes. 1994;43:741–745
  33. Katz LEL, Weinzimer SA, McKnight H, Murphy KM. Clinical follow-up course of antibody-negative obese children with acanthosis nigricans presenting with diabetic ketoacidosis (DKA). Pediatr Res. 2002;51(pt 2; Suppl 24S):123A–124A
  34. Sapru A, Gitelman SE, Bhatia S, Dubin RF, Newman TB, Flori H. Prevalence and characteristics of type 2 diabetes mellitus in 9-18 year old children with diabetic ketoacidosis. J Pediatr Endocrinol Metab. 2005;18:865–872
  35. Today Study Grp. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone of lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes. 2007;8:74–87

 Supported by the National Center for Research Resources (grant UL1-RR-024134). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. The authors declare no conflicts of interest.

PII: S0022-3476(10)00589-5

doi: 10.1016/j.jpeds.2010.07.011

The Journal of Pediatrics
Volume 158, Issue 1 , Pages 106-111 , January 2011

Article Tools

* Image Usage & Resolution